Navigation Links
Philippe Généreux, MD, presented with 2012 TCT Young Investigator Award
Date:10/26/2012

MIAMI, FL OCTOBER 26, 2012 Philippe Gnreux, MD was presented the TCT 2012 Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award in a ceremony held today during the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The award is given each year to a promising researcher in the field of interventional cardiovascular medicine. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiology.

The award honors the memory of Thomas J. Linnemeier, MD, the former chief of the Indiana Heart Institute, senior vice president of New Ventures, and chief medical officer of Vascular Intervention at Guidant Corp. The purpose of the award, which is accompanied by a $10,000 grant, is to encourage the recipient to maintain a continued commitment and dedication to both patient care and academic research.

An outstanding young academician and a prolific writer, Dr. Philippe Gnreux is a practicing Interventional Cardiologist at Hpital du Sacr-Coeur de Montral. Dr. Gnreux also serves as the Director of the Angiographic Core Laboratory at the CRF Clinical Trials Center where he leads the lab's coronary, peripheral, and structural imaging analyses and services. He received his medical degree from the Universit de Montral, Qubec, Canada, and is currently pursuing a PhD at Erasmus University in Rotterdam, The Netherlands. His research interests include coronary risk stratification/Syntax score, coronary physiology and imaging, percutaneous aortic valve replacement, transradial intervention, drug-eluting stent innovation, and medical simulation.

The winner was selected by Drs. Sheldon Goldberg, Howard C. Herrmann, John W. Hirshfeld Jr. and Robert L. Wilensky from Philadelphia. Gregg W. Stone, MD and Howard C. Hermann, MD jointly presented the award. Dr. Stone is Professor of Medicine at Columbia University College of P
'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Results of the XIMA trial presented at TCT 2012
2. Barry D. Rutherford, M.D. presented with Master Clinical Operator Award at TCT 2012
3. Renu Virmani, M.D. presented with 2012 TCT Career Achievement Award
4. Results of the AIDA STEMI MRI sub-study presented at TCT 2012
5. Results of the PC trial presented at TCT 2012
6. Results of the POSEIDON trial presented at TCT 2012
7. 1-year results of ADAPT-DES presented at TCT 2012
8. CRF announces late breaking trials and first report investigations to be presented at TCT 2012
9. New clinical guidelines for managing hypothyroid disease presented in Thyroid Journal
10. Research presented at TCT 2012 will have significant impact on interventional cardiology
11. Typical IBD patients not represented in research studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... The report, “Heat Transfer Fluids Market by Type ... & Others), by Application (Oil & Gas, Chemical, CSP, ... & Forecasts to 2019” defines and segments the global ... of the global consumption in terms of volume and ... spread through 199 page sand in-depth TOC on"Heat Transfer ...
(Date:7/29/2014)... New York (PRWEB) July 29, 2014 ... mount in U.S. courts, Bernstein Liebhard LLP notes that ... medications in men with Type 2 diabetes. The research, ... Endocrinology & Metabolism on June 30th, involved 88 men ... had mild to moderate aging male symptoms and erectile ...
(Date:7/29/2014)... negotiations may depend on more than diplomacy. When it comes ... according to a new study. Researchers found ... for themselves than men with narrower faces. However, having ... require collaboration and compromise, the researchers found. "We negotiate ... not just the big things, like a car or a ...
(Date:7/29/2014)... Society of America (GSA) and the National Center ... PhD, of Columbia University as the 2014 recipient of ... Aging. , This award recognizes and honors the seminal ... field of creativity and aging shifted the conceptual focus ... potential. Cohen inspired individuals to approach longevity asking what ...
(Date:7/29/2014)... in boys with fragile X syndrome tend to ... study of the inherited disorder to date has ... everyday social and practical skills, including communication, socialization, ... getting dressed. In this study, socialization emerged as ... in that it did not decline as much ...
Breaking Medicine News(10 mins):Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 2Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 3Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 4Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 2Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 4Health News:Wider Face May Give You an Edge in Negotiations 2Health News:Charon to receive 2014 Gene D. Cohen Award 2Health News:Socialization relative strength in fragile X longitudinal study 2
... HILL, N.C., Feb. 19 With sales forces ... the constant,demand for rep time, winning a place ... response, leading pharma companies are relying on,specialized training ... process within the hospital environment, according to recent,research ...
... WYE ),announced today that The Honorable Stuart R. ... Maryland, has granted Wyeth,s motion for,summary judgment in the ... al -- an alleged vaccine injury case claiming that ... autistic., Previously, the Court had granted Wyeth,s motion ...
... PARK, Fla., Feb. 19 Transitionz Wellness,Boutique is ... or adult, who,is a cancer survivor, is going ... is trying to get well, and we are ... of the best products and services,including wigs, hats, ...
... A new technique developed by a University of Central ... bacterial infections patients have so they can be treated ... strains resistant to many drugs emerge, it becomes more ... would most effectively treat them. Such quick identifications become ...
... new study released,today found that pending congressional legislation ... technologies would likely result,in increased prices and "provide ... released today at the National Press Club by ... and senior fellow at,the American Enterprise Institute, and ...
... response to recent media,reports, Roche would like to reaffirm ... medication for the 2007-2008,flu season, and that physicians and ... flu strikes., Some news reports have indicated "shortages" ... in place to ensure that Tamiflu is readily,available. If ...
Cached Medicine News:Health News:Building an Effective Sales Force to Serve the U.S. Hospital Market 2Health News:Wyeth Wins Thimerosal-Autism Case in Maryland Court 2Health News:Wyeth Wins Thimerosal-Autism Case in Maryland Court 3Health News:Transitionz Wellness Boutique Launches with Grand Opening Discounts 2Health News:UCF technique promises to aid doctor's ability to identify, treat bacterial infections 2Health News:New Report Finds Mandatory Price Disclosure for Med Tech Would Likely Increase Prices 2Health News:Press Statement: Roche Affirms That Tamiflu(R) is in Ample Supply Nationwide 2
(Date:7/29/2014)... , July 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... participating in two healthcare conferences during the third quarter, ... Morgan Stanley Global Healthcare 2014 Conference.  Alexza,s corporate presentation ... The details on each event are below: ... 11, 2014 in Boston , MA.  ...
(Date:7/29/2014)... GLENWOOD, Ill. , July 29, 2014  Landauer, ... in personal and environmental radiation measurement and monitoring, outsourced ... will release financial results for the fiscal third quarter ... 2014. The Company will host a ... at 9:00 a.m. Central Time (10 a.m. Eastern Time). ...
(Date:7/29/2014)... (NYSE: CVD ) today reported results for ... was $639 million, representing 8.0% growth from the second ... reported earnings of $0.29 per diluted share in the ... diluted share of $0.95, up 21.5% over the second ... charges totaling $52.6 million, or $0.61 per share, and ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24
... ENDOPATH EZ45 Endoscopic Linear Cutter has application ... surgical procedures for transection, resection, and/or creation ... staple line or tissue buttressing materials such ... reloaded seven times for a total of ...
... Linear Cutters provide a 45mm staple and ... the device suitable for many minimally invasive ... transection, resection, and/or creation of anastomoses in ... ,The LONG45A Endocutter has a shaft ...
ACUCLIP Endoscopic Right-Angle Multiple Clip Applier, 10 mm Shaft Diameter with 20, 8 mm Titanium Clips...
Insert only, Pilling-Weck medium clip size...
Medicine Products: